Autologous bone marrow mononuclear cell therapy versus standard treatment for critical limb ischemia and diabetic foot

Phase 2, randomised, open-label trial of autologous bone marrow-derived mononuclear cell in chronic limb-threatening ischemia (CLTI) and diabetic foot syndrome (2 arms), sponsored by Institute for Clinical and Experimental Medicine. Primary endpoint: Comparison of cell therapy with standard treatment in several parameters. Started Apr 2016; status: completed.